Direct angiotensin II type 2 receptor stimulation in N ω- nitro-L-arginine-methyl ester-induced hypertension: The effect on pulse wave velocity and aortic remodeling

Hypertension

Volumn 59, Issue 2 SUPPL. 1, 2012, Pages 485-492

  Paulis, Ludovit ^a,b   Becker, Sophie T R ^a   Lucht, Kristin ^a   Schwengel, Katja ^a   Slavic, Svetlana ^a   Kaschina, Elena ^a   Thöne Reineke, Christa ^a   Dahlöf, Björn ^c   Baulmann, Johannes ^d   Unger, Thomas ^a   Steckelings, U Muscha ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Faculty of Medicine of Comenius University and University Hospital Bratislava   (Slovakia)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF LÜBECK   (Germany)

Author keywords

arterial stiffness; hypertension; L NAME; pulse wave velocity; renin angiotensin system; vascular remodeling

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; ANTIHYPERTENSIVE AGENT; COMPOUND 21; HYDROXYPROLINE; N(G) NITROARGININE METHYL ESTER; OLMESARTAN; UNCLASSIFIED DRUG; HORMONE RECEPTOR STIMULATING AGENT; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; COLLAGEN; IMIDAZOLE DERIVATIVE; N BUTYLOXYCARBONYL 3 (4 IMIDAZOL 1 YLMETHYLPHENYL) 5 ISOBUTYLTHIOPHENE 2 SULFONAMIDE; N-BUTYLOXYCARBONYL-3-(4-IMIDAZOL-1-YLMETHYLPHENYL)-5-ISOBUTYLTHIOPHENE-2-SULFONAMIDE; SULFONAMIDE; TETRAZOLE DERIVATIVE; THIOPHENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; BLOOD PRESSURE; CONFERENCE PAPER; CONTROLLED STUDY; HYPERTENSION; MALE; NONHUMAN; PRIORITY JOURNAL; PULSE WAVE; RAT; TREATMENT DURATION; ANTIHYPERTENSIVE THERAPY; AORTA RECONSTRUCTION; AORTA REMODELING; BLOOD PRESSURE MEASUREMENT; RECEPTOR BLOCKING; YOUNG MODULUS; ANIMAL; AORTA; ARTICLE; BLOOD FLOW VELOCITY; BODY WEIGHT; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG EFFECT; DRUG POTENTIATION; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PULSATILE FLOW; WISTAR RAT;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; AORTA; BLOOD FLOW VELOCITY; BLOOD PRESSURE; BODY WEIGHT; COLLAGEN; DISEASE MODELS, ANIMAL; HYDROXYPROLINE; HYPERTENSION; IMIDAZOLES; MALE; NG-NITROARGININE METHYL ESTER; PULSATILE FLOW; RATS; RATS, WISTAR; RECEPTOR, ANGIOTENSIN, TYPE 2; SULFONAMIDES; TETRAZOLES; THIOPHENES; VASCULAR STIFFNESS;

EID: 84856201427     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.111.185496     Document Type: Conference Paper

References (52)

1. Redwood H. Hypertension, society, and public policy. Eur Heart J. 2007;9(suppl):B13-B18.
2. Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampaoli S, Joffres MR, Poulter N, Primatesta P, Stegmayr B, Thamm M. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension. 2004;43:10-17. (Pubitemid 38031904)
3. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, Pannier B, Vlachopoulos C, Wilkinson I, Struijker-Boudier H; European Network for Non-invasive Investigation of Large Arteries. Expert consensus document on arterial stiffness: Methodological issues and clinical applications. Eur Heart J. 2006;27:2588-2605. (Pubitemid 44627304)
4. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 guidelines for the management of arterial hypertension. Eur Heart J. 2007;28:1462-1536.
5. Paulis L, Unger T. Novel therapeutic targets for hypertension. Nat Rev Cardiol. 2010;7:431-441.
6. Unger T, Paulis L, Sica DA. Therapeutic perspectives in hypertension: Novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches. Eur Heart J. 2011;32:2739-2747.
7. Tomiyama H, Yoshida M, Yamada J, Matsumoto C, Odaira M, Shiina K, Yamashina A. Arterial-cardiac destiffening following long-term antihypertensive treatment. Am J Hypertens. 2011;24:1080-1086.
8. Dhakam Z, McEniery CM, Yasmin, Cockcroft JR, Brown MJ, Wilkinson IB. Atenolol and eprosartan: Differential effects on central blood pressure and aortic pulse wave velocity. Am J Hypertens. 2006;19:214-219. (Pubitemid 43350177)
9. Agata J, Nagahara D, Kinoshita S, Takagawa Y, Moniwa N, Yoshida D, Ura N, Shimamoto K. Angiotensin II receptor blocker prevents increased arterial stiffness in patients with essential hypertension. Circ J. 2004;68: 1194-1198. (Pubitemid 40018867)
10. Takami T. Evaluation of arterial stiffness in morning hypertension under high-dose valsartan compared to valsartan plus low-dose diuretic. Hypertens Res. 2009;32:1086-1090.
11. Asmar RG, London GM, O'Rourke ME, Safar ME; REASON Project Coordinators and Investigators. Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/ indapamide combination in hypertensive patient: A comparison with atenolol. Hypertension. 2001;38:922-926. (Pubitemid 34258694)
12. Mackenzie IS, McEniery CM, Dhakam Z, Brown MJ, Cockroft JR, Wilkinson IB. Comparison of the effects of antihypertensive agents on central blood pressure and arterial stiffness in isolated systolic hypertension. Hypertension. 2009;54:409-413.
13. Pannier BM, Guerin AP, Marchais SJ, London GM. Different aortic reflection wave responses following long-term angiotensin-converting enzyme inhibition andβ-blocker in essential hypertension. Clin Exp Pharmacol Physiol. 2001;28:1074-1077. (Pubitemid 34053527)
14. Mourad JJ, Girerd X, Boutouyrie P, Laurent S, Safar M, London G. Increased stiffness of radial artery wall material in end-stage renal disease. Hypertension. 1997;30:1425-1430. (Pubitemid 27528085)
15. Guerin AP, Blacher J, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation. 2001;103:987-992. (Pubitemid 32183805)
16. Rompe F, Artuc M, Hallberg A, Alterman M, Ströder K, Thöne-Reineke C, Reichenbach A, Schacherl J, Dahlöf B, Bader M, Alenina N, Schwaninger M, Zuberbier T, Funke-Kaiser H, Schmidt C, Schunck WH, Unger T, Steckelings UM. Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor kappaB. Hypertension. 2010;55:924-931.
17. Rompe F, Unger T, Steckelings UM. The angiotensin AT2 receptor in inflammation. Drug News Perspect. 2010;23:104-111.
18. Steckelings UM, Widdop RE, Paulis L, Unger T. The angiotensin AT2 receptor in left ventricular hypertrophy. J Hypertens. 2010;28:S50-S55.
19. Steckelings UM, Rompe F, Kaschina E, Namsolleck P, Grzesiak A, Funke-Kaiser H, Bader M, Unger T. The past, present and future of angiotensin II type 2 receptor stimulation. J Renin Angiotensin Aldosterone Syst. 2010;11:67-73.
20. Matavelli LC, Huang J, Siragy HM. Angiotensin AT2 receptor stimulation inhibits early renal inflammation in renovascular hypertension. Hypertension. 2011;57:308-313.
21. Min LJ, Cui TX, Yahata Y, Yamasaki K, Shichi T, Liu HW, Chen R, Li JM, Okumura M, Jinno T, Wu L, Iwai M, Nahmias C, Hashimoto K, Horiuchi M. Regulation of collagen synthesis in mouse skin fibroblasts by distinct angiotensin II receptor subtypes. Endocrinology. 2004;145: 253-260. (Pubitemid 38202166)
22. Ribeiro MO, Antunes E, de-Nucci G, Lovisolo SM, Zatz R. Chronic inhibition of nitric oxide synthesis: A new model of arterial hypertension. Hypertension. 1992;20:298-303.
23. Johnson RA, Freeman RH. Sustained hypertension in the rat induced by chronic blockade of nitric oxide production. Am J Hypertens. 1992;5: 919-922. (Pubitemid 23022579)
24. Paulis L, Pechanova O, Zicha J, Barta A, Gardlik R, Celec P, Kunes J, Simko F. Melatonin interactions with blood pressure and vascular function during L-NAME-induced hypertension. J Pineal Res. 2010;48: 102-108.
25. Paulis L, Matuskova J, Adamcova M, Pelouch V, Simko J, Krajcirovicova K, Potacova A, Hulin I, Janega P, Pechanova O, Simko F. Regression of left ventricular hypertrophy and aortic remodelling in NO-deficient hypertensive rats: Effect of L-arginine and spironolactone. Acta Physiol (Oxf). 2008;194:45-55.
26. Rossi MA, Colombini-Netto M. Chronic inhibition of NO synthesis per se promotes structural intimal remodeling of the rat aorta. J Hypertens. 2001;19:1567-1579. (Pubitemid 32783774)
27. Kameyama H, Takeda K, Kusaba T, Narumiya H, Tanda S, Kuwahara N, Yamada K, Tamagaki K, Okigaki M, Hatta T, Sasaki S. Augmentation of pulse wave velocity precedes vascular structural changes of the aorta in rats treated with N(omega)-nitro-L-arginine methyl ester. Hypertens Res. 2005;28:439-445. (Pubitemid 41007459)
28. Fitch RM, Vergona R, Sullivan ME, Wang YX. Nitric oxide synthase inhibition increases aortic stiffness measured by pulse wave velocity in rats. Cardiovasc Res. 2001;51:351-358. (Pubitemid 32695546)
29. Nichols WN, O'Rourke MF. Vascular impedance. In:McDonald's Blood Flow in Arteries: Theoretical, Experimental and Clinical Principles. 4th ed. London, United Kingdom: Edward Arnold; 1998;54 -97, 243-283, 347-395.
30. Reddy GK, Enwemeka CS. A simlified method for the analysis of hydroxyproline in biological tissues. Clin Biochem. 1996;29:225-229. (Pubitemid 26142071)
31. Simko F, Matuskova J, Luptak I, Pincikova T, Krajcirovicova K, Stvrtina S, Pomsar J, Pelouch V, Paulis L, Pechanova O. Spironolactone differently influences remodeling of the left ventricle and aorta in L-NAMEinduced hypertension. Physiol Res. 2007;56:S25-S32.
32. Paulis L, Zicha J, Kunes J, Hojna S, Behuliak M, Celec P, Kojsova S, Pechanova O, Simko F. Regression of L-NAME-induced hypertension: The role of nitric oxide and endothelium-derived constricting factor. Hypertens Res. 2008;31:793-803. (Pubitemid 351772871)
33. Paulis L, Pechanova O, Zicha J, Krajcirovicova K, Barta A, Pelouch V, Adamcova M, Simko F. Melatonin prevents fibrosis but not hypertrophy development in the left ventricle of NG-nitro-L-arginine-methyl ester hypertensive rats. J Hypertens. 2009;27(suppl):S11-S16.
34. Blacher J, Asmar R, Djane S, London GM, Safar ME. Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients. Hypertension. 1999;33:1111-1117. (Pubitemid 29230958)
35. Isnard RN, Pannier BM, Laurent S, London GM, Diebold B, Safar ME. Pulsatile diameter and elastic modulus of the aortic arch in essential hypertension: A noninvasive study. J Am Coll Cardiol. 1989;13:399-405. (Pubitemid 19055665)
36. Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L, Ducimetiere P, Benetos A. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension. 2002;37:1236-1241.
37. Boutourye P, Tropeano AI, Asmar R, Gautir I, Benetos A, Lacolley P, Laurent S. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: A longitudinal study. Hypertension. 2002;39:10-15. (Pubitemid 34098081)
38. Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness on survival in end-stage renal disease. Circulation. 1999;99:2434-2439. (Pubitemid 29218240)
39. Meaume S, Benetos A, Henry OF, Rudnichi A, Safar ME. Aortic pulse wave velocity predicts cardiovascular mortality in subjects >70 years of age. Arterioscler Thromb Vasc Biol. 2001;21:2046-2050. (Pubitemid 34219760)
40. Willum-Hansen T, Staessen JA, Torp-Pedersen C, Rasmussen S, Thijs L, Ibsen H, Jeppesen J. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation. 2006; 113:664-670.
41. Maldonado J, Pereira T, Polónia J, Silva JA, Morais J, Marques M; participants in the EDIVA Project. Arterial stiffness predicts cardiovascular outcome in a low-to-moderate cardiovascular risk population: The EDIVA (Estudo de DIstensibilidade VAscular) project. J Hypertens. 2011;29:669-675.
42. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: A systematic review and meta-analysis. J Am Coll Cardiol. 2010;55:1318-1327.
43. Asmar RG, Pannier B, Santoni JP, Laurent S, London GM, Levy BI, Safar ME. Reversion of cardiac hypertrophy and reduced arterial compliance after converting enzyme inhibition in essential hypertension. Circulation. 1988;78:941-950.
44. Ong mT, Delerme S, Pannier B, Safar M, Benetos A, Laurent S, Boutouyrie P. Aortic stiffness is reduced beyond blood pressure lowering by short-term and long-term antihypertensive treatment: A meta-analysis of individual data in 294 patients. J Hypertens. 2011;29:1034-1042.
45. Yoshino T, Nakae I, Matsumoto T, Mitsunami K, Horie M. Association between brachial-ankle pulse wave velocity and endothelium-dependent and -independent coronary vasomotor function. Clin Exp Pharmacol Physiol. 2011;38:34-41.
46. McCall DO, McGartland CP, Woodside JV, Sharpe P, McCance DR, Young IS. The relationship between microvascular endothelial function and carotid-radial pulse wave velocity in patients with mild hypertension. Clin Exp Hypertens. 2010;32:474-479.
47. Wilkinson IB, MacCallum H, Cockcroft JR, Webb DJ. Inhibition of basal nitric oxide synthesis increases aortic augmentation index and pulse wave velocity in vivo. Br J Clin Pharmacol. 2002;53:189-192. (Pubitemid 34264274)
48. Bernatova I, Pechanova O, Kristek F. Mechanism of structural remodelling of the rat aorta during long-term NG-nitro-L-arginine methyl ester treatment. Jpn J Pharmacol. 1999;81:99-106. (Pubitemid 29479061)
49. Kaschina E, Grzesiak A, Li J, Foryst-Ludwig A, Timm M, Rompe F, Sommerfeld M, Kemnitz UR, Curato C, Namsolleck P, Tschöpe C, Hallberg A, Alterman M, Hucko T, Paetsch I, Dietrich T, Schnackenburg B, Graf K, Dahlöf B, Kintscher U, Unger T, Steckelings UM. Angiotensin II type 2 receptor stimulation: A novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction? Circulation. 2008;118:2523-2532.
50. Vlachopoulos C, Dima I, Aznaouridis K, Vasiliadou C, Ioakeimidis N, Aggeli C, Toutouza M, Stefanadis C. Acute systemic inflammation increases arterial stiffness and decreases wave reflections in healthy individuals. Circulation. 2005;112:2193-2200. (Pubitemid 41475815)
51. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology: XXIII-the angiotensin II receptors. Pharmacol Rev. 2000;52:415-472.
52. Wan Y, Wallinder C, Plouffe B, Beaudry H, Mahalingam AK, Wu X, Johansson B, Holm M, Botoros M, Karlén A, Pettersson A, Nyberg F, Fändriks L, Gallo-Payet N, Hallberg A, Alterman M. Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J Med Chem. 2004;47:5995-6008. (Pubitemid 39507341)